This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Díaz, L. A. Articles by Restrepo, M. I. Search for Related Content PubMed PubMed Citation Articles by Díaz, L. A. Articles by Restrepo, M. I. Pubmed/NCBI databases Medline Plus Health Information Pneumonia Social Bookmarking                         What's this?

Review: Novel targets in the management of pneumonia

Geisinger Health System and Fundación Universitaria de Ciencias de la Salud, Hospital de San José, Bogotá DC, Colombia

Eric M. Mortensen

General Internal Medicine, VERDICT, South Texas Veterans Health Care System and Audie L Murphy Division, University of Texas Health Science Center, San Antonio, USA

Antonio Anzueto

Division of Pulmonary and Critical Care Medicine, South Texas Veterans Health Care System and Audie L Murphy Division, University of Texas Health Science Center, San Antonio, USA

Marcos I. Restrepo

Division of Pulmonary and Critical Care Medicine, VERDICT, South Texas Veterans Health Care System and Audie L Murphy Division, University of Texas Health Science Center, San Antonio, USA, restrepom{at}uthscsa.edu

Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.

Key Words: community-acquired infections • pneumonia • therapeutics • intensive care unit

Therapeutic Advances in Respiratory Disease, Vol. 2, No. 6, 387-400 (2008)
DOI: 10.1177/1753465808098694


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?